https://pubmed.ncbi.nlm.nih.gov/38113329

The study found that early response assessment with FDG PET/CT predicts progression-free survival in advanced melanoma patients treated with BRAF/MEK inhibitors, but new FDG-avid lesions during treatment may not always indicate disease progression.